Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine
Amneal to Report First Quarter 2024 Results on May 3, 2024
Enforcement Report - Week of April 3, 2024
Amneal to Ring the Nasdaq Closing Bell on April 2, 2024
Amneal Pharmaceuticals is recalling four lots of an antibacterial after a manufacturing error may have resulted in overfilled bottles.
Amneal Pharm Generic Lacosamide Receives Approval in the U.S.
Amneal Pharmaceuticals, LLC. Issues a Nationwide Voluntary Recall of Vancomycin Hydrochloride
Amneal gains FDA greenlight to develop Ciprodex generic for ear infections
Amneal Receives FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension
Enforcement Report - Week of February 28, 2024